Biotech Gene Therapy Names Juno, Kite, And bluebird bio Still Have Room To Run – Seeking Alpha
|
Biotech Gene Therapy Names Juno, Kite, And bluebird bio Still Have Room To Run
Seeking Alpha This report highlights a trio of gene therapy names with additional upside for investors with an 18-month time horizon. BLUE should net at least $150,000 per patient with demand from (and capacity to treat) thousands of patients annually by 2020-2022. |
